Skip to content
RecruitingPhase 2

Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD

NCT05732155 · Guy Schusheim

Recruiting
Status
Accepting participants
Phase 2
Phase
60
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with war-related Post traumatic Stress Disorder, in a hybrid individual and group treatment protocol. The overall safety objective is to assess the severity, incidence, and frequency of AEs, AEs of Special Interest (AESIs), and Serious Adverse Events (SAEs), concomitant medication use, suicidal ideation and behavior and vital signs .

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Change from pre-treatment baseline to post-treatment in CAPS-5 total score

    Measured over From baseline to V18, approximately 18 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria * Experienced war-related trauma. * Fluent in speaking and reading Hebrew. * Able to swallow capsules. * Willing to have study visits, including MDMA experimental sessions and non-drug psychotherapy sessions, audio- and/or video-recorded as specified by the protocol. * Able to identify a relative, spouse, close friend, or other support person who can be contacted by the investigators if the participant becomes suicidal or cannot be reached. * Agrees to inform the investigators within 48 hours of relevant medical conditions or procedures. * Agrees to comply with study requirements, including fasting and medication restrictions before experimental sessions, refraining from participation in other interventional clinical trials during the study, remaining overnight at the study site after each experimental session, arranging accompanied transportation after discharge, and complying with study medication, psychotherapy, and assessment procedures. * At screening, meets DSM-5 criteria for current PTSD of the protocol-specified minimum duration. * At screening, has at least moderate PTSD symptom severity, defined as a CAPS-5 total score of 28 or greater. Exclusion Criteria * Unable to provide adequate informed consent. * Use of Ecstasy or material represented as containing MDMA more than 10 times during the previous 10 years, or any such use within 6 months before the first experimental session. * Previous participation in a MAPS-sponsored MDMA clinical trial. * Any current medical, psychiatric, psychosocial, or other condition that, in the judgment of the investigator or study physician, could interfere with safe or effective participation. * Known sensitivity or allergy to MDMA or another study intervention that, in the judgment of the sponsor-investigator or study clinician, contraindicates participation. * Electroconvulsive therapy within 12 weeks before enrollment. * Current or lifetime primary psychotic disorder. * Current eating disorder involving active purging, as assessed by the MINI and clinical interview. * Current major depressive disorder with psychotic features, as assessed by the MINI. * Current alcohol or substance use disorder judged by the investigators, therapy team, or study physician to represent a safety concern. * Active illicit-drug or prescription-drug substance use disorder, other than caffeine or nicotine use disorder, within 12 months before enrollment, as defined by the protocol. * Current personality disorder meeting the protocol-specified exclusion criteria. * Current serious suicide risk. * Requirement for ongoing treatment with a psychiatric medication that cannot be discontinued or is not permitted under the protocol, except as specified in the concomitant-medication provisions. * Medical condition for which exposure to a sympathomimetic drug or associated increases in blood pressure or heart rate would pose an unacceptable risk. * Uncontrolled hypertension, defined according to the protocol as blood pressure of 140/90 mmHg or higher on three separate occasions. * History of ventricular arrhythmia other than premature ventricular contractions in the absence of ischemic heart disease. * Wolff-Parkinson-White syndrome or another accessory conduction pathway that has not been successfully treated by ablation. * History of clinically significant arrhythmia within 12 months before screening, other than premature atrial contractions or occasional premature ventricular contractions in the absence of ischemic heart disease. * Baseline QTc prolongation greater than 450 ms in males or greater than 460 ms in females, corrected using Fridericia's formula. * Additional risk factors for torsade de pointes, including heart failure, hypokalemia, or a family history of long-QT syndrome. * Requirement for concomitant medications that prolong the QT/QTc interval during experimental sessions. * Symptomatic liver disease or clinically significant liver-enzyme elevations. * History of hyponatremia or hyperthermia. * Body weight below 48 kg. * Ketamine-assisted therapy or ketamine use within 12 weeks before enrollment.

Where

1 study site

FacilityCityRegionCountry
Emek medical centerAfula-Israel

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record. The registry also holds the most current version of everything above.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05732155 on ClinicalTrials.gov →

Last updated in the registry 2026-10-15. Registry records change; this page reflects the data build of 2026-11-10.

Related

Where this trial sits